Celyad Oncology SA Cash Flow 2022-2011 | CYAD

Brief overview of Celyad Oncology SA's cash generation

This overview follows the five latest available annual observations in the 2018–2022 interval.

At the end of the period, operations consumed -€28 million rather than generating cash. This profile calls for caution.

Core operations generated cash in 0 of five years. Frequent negative periods raise financial risk.

What the cash flows show

Celyad Oncology SA has limited cash flow resilience; a return to stable positive cash generation is the main condition for improvement.

Annual Cash Flow Celyad Oncology SA

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Operating Cash Flow	-28 M	-26.6 M	-27.7 M	-28.2 M	-27.2 M	-44.4 M	-24.7 M	-27.3 M	-	-	-	-

All numbers in EUR currency

Quarterly Cash Flow Celyad Oncology SA

	2023-Q2	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Operating Cash Flow	-8.33 M	-28 M	-	-16.3 M	-	-26.6 M	-	-12.2 M	-	-27.7 M	-	-14.6 M	-	-28.2 M	-	-16.1 M	-	-27.2 M	-	-	-	-44.4 M	-	-	-	-24.7 M	-	-	-	-27.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Cash Flow Statement is one of the three key financial reports of the company Celyad Oncology SA, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement

Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer	Price	% 24h	Market Cap	Country
Takeda Pharmaceutical Company Limited TAK	$ 19.67	1.08 %	$ 31.1 B	Japan
Revolution Medicines RVMD	$ 177.96	0.22 %	$ 33.8 B	USA
Rhythm Pharmaceuticals RYTM	$ 86.17	0.6 %	$ 5.6 B	USA
Prelude Therapeutics Incorporated PRLD	$ 3.26	0.9 %	$ 251 M	USA
Sana Biotechnology SANA	$ 2.27	6.22 %	$ 575 M	USA
Pulmatrix PULM	$ 1.36	4.61 %	$ 4.97 B	USA
Zoetis ZTS	$ 79.38	1.22 %	$ 35.2 B	USA
Ultragenyx Pharmaceutical RARE	$ 14.54	1.81 %	$ 1.43 B	USA
XTL Biopharmaceuticals Ltd. XTLB	$ 1.96	2.62 %	$ 1.32 B	Israel
Zymeworks ZYME	$ 25.03	0.16 %	$ 1.29 B	Canada
AC Immune SA ACIU	$ 2.39	2.08 %	$ 241 M	Schweiz
Adagene ADAG	$ 2.06	4.8 %	$ 122 M	China
Adial Pharmaceuticals ADIL	$ 3.49	11.15 %	$ 2.33 M	USA
ADC Therapeutics SA ADCT	$ 1.4	0.34 %	$ 178 M	Schweiz
ADMA Biologics ADMA	$ 10.68	3.77 %	$ 2.55 B	USA
Assembly Biosciences ASMB	$ 20.09	0.19 %	$ 225 M	USA
Allogene Therapeutics ALLO	$ 1.31	3.08 %	$ 289 M	USA
Amgen AMGN	$ 432.49	0.08 %	$ 233 B	USA
Ardelyx ARDX	$ 3.09	2.51 %	$ 745 M	USA
Armata Pharmaceuticals ARMP	$ 3.37	9.06 %	$ 122 M	USA
Artelo Biosciences ARTL	$ 2.7	0.36 %	$ 511 K	USA
Bicycle Therapeutics plc BCYC	$ 3.46	2.56 %	$ 240 M	Britain
Beam Therapeutics BEAM	$ 23.47	4.57 %	$ 2.32 B	USA
Benitec Biopharma BNTC	$ 8.11	2.05 %	$ 378 M	USA
BioNTech SE BNTX	$ 87.71	1.74 %	$ 21.2 B	Germany
ANI Pharmaceuticals ANIP	$ 72.29	0.01 %	$ 1.45 B	USA
C4 Therapeutics CCCC	$ 2.77	0.36 %	$ 230 M	USA
Cerus Corporation CERS	$ 2.18	0.66 %	$ 415 M	USA
Certara CERT	$ 9.37	0.26 %	$ 1.5 B	USA
Coherus BioSciences CHRS	$ 0.99	1.9 %	$ 116 M	USA
Corcept Therapeutics Incorporated CORT	$ 110.16	0.47 %	$ 11.4 B	USA
CorMedix CRMD	$ 7.26	0.95 %	$ 523 K	USA
CRISPR Therapeutics AG CRSP	$ 49.25	2.59 %	$ 4.43 B	Schweiz
Greenwich LifeSciences GLSI	$ 14.55	1.48 %	$ 197 M	USA
Champions Oncology CSBR	$ 4.7	0.94 %	$ 65 M	USA
Cue Biopharma CUE	$ 16.71	0.38 %	$ 1.58 B	USA
DBV Technologies S.A. DBVT	$ 9.05	2.71 %	$ 1.26 B	France
Alterity Therapeutics Limited ATHE	$ 2.62	8.64 %	$ 16.8 B	Australia
Actinium Pharmaceuticals ATNM	$ 1.13	6.6 %	$ 35.3 M	USA
DiaMedica Therapeutics DMAC	$ 7.57	0.75 %	$ 356 M	USA